🇺🇸 FDA
Pipeline program

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

R5458-ONC-2012

Phase 1 other active

Quick answer

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments for Relapsed/Refractory Multiple Myeloma is a Phase 1 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 1
Modality
other
Status
active

Clinical trials